Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TYMP | P19971 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26735103 | 1.00 | TK1 (0.46) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL26738168 | 1.00 | TK1 (0.46) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL24263989 | 1.00 | TK1 (0.46) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL14639895 | 0.91 | ALDH1A1 (0.43) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL14853815 | 0.89 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL7128636 | 0.89 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL1097570 | 0.89 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL856694 | 0.89 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL2767589 | 0.89 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL19258430 | 0.89 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | claimed |
| US-8957201-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-17 | — | — | US | claimed |
| US-7034133-B2 | Locked Nucleoside Analogues is a biochemical conjugate of nucleotides; as an aptamer in specific binding of antibiotics, drugs, amino acids, peptides, enzymes, saccharides, polysaccharides; heat resistance | EXIQON A/S (DK) | 2006-04-25 | — | — | US | claimed |
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-2305805-B1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | PFAS, ENPP1, NAAA | TK1 726/4885ALDH1A1 2704/4885LMNA 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.